ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

Rhea-AI Summary

ERYTECH Pharma will host its Second Quarter 2021 conference call on September 21, 2021, at 2:30 PM CEST/8:30 AM ET. The call aims to discuss operational highlights, and registration is required for participation, which can be completed via the provided link. A live webcast will also be available. ERYTECH is focused on developing innovative red blood cell-based therapies for cancer and orphan diseases using the ERYCAPS® platform. The company’s lead product, eryaspase, is in Phase 3 trials for second-line pancreatic cancer.

ERYTECH to Host on September 21, 2021
Second Quarter 2021 conference call and Business Update

---

Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights.

The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)
Once registered, participants will receive a unique access code and the call number details to join the teleconference.

The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4.

An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6866536#.

An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com

About ERYTECH

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        

For more information, please visit www.erytech.com        

CONTACTS
  

ERYTECH                      Eric Soyer CFO & COO	LifeSci Advisors, LLC Corey Davis, Ph.D. Investor Relations	NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations
+33 4 78 74 44 38 investors@ERYTECH.com	+1 (212) 915 - 2577 cdavis@lifesciadvisors.com	+33 1 44 71 94 94 ERYTECH@newcap.eu

Attachment

• ERYTECH_PR_2021_H1_Ccall-announcement_EN

FAQ

When is the ERYTECH Pharma second quarter 2021 conference call?

The conference call is scheduled for September 21, 2021, at 2:30 PM CEST/8:30 AM ET.

How can I access the ERYTECH Pharma conference call?

Participants can register for the conference call using the link provided in the press release.

What is the focus of ERYTECH Pharma's research?

ERYTECH Pharma is focused on developing red blood cell-based therapies targeting cancer and orphan diseases.

What is the status of eryaspase in clinical trials?

Eryaspase is in Phase 3 clinical development for second-line pancreatic cancer and is fully enrolled.

Where can I find the archived replay of the ERYTECH Pharma call?

An archived replay can be accessed by dialing +1 855 859 2056 with Conference ID 6866536#.